11:11 PM
 | 
Feb 24, 2019
 |  BC Extra  |  Company News

Spark gives Roche beachhead in gene therapy

Editor's Note: This article was updated on Feb 25, 2019 at 1:44 PM PST

Roche (SIX:ROG; OTCQX:RHHBY) will acquire Spark Therapeutics Inc. (NASDAQ:ONCE) for $4.8 billion in a deal that marks the Swiss pharma's first major move into gene therapy.

The deal announced early Monday was the first major acquisition since James Sabry became global head of pharma partnering (see “Roche’s Partnering Priority”).

Roche will pay Spark shareholders $114.50 per share in cash. The price represents a 126% premium to Spark’s close of $50.61 on Friday. Spark gained $61.92 (120%) to $113.48 Monday.

The takeout price is a 24% premium to Spark’s all-time share price...

Read the full 442 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >